SCHEMBL2904916

SCHEMBL2904916

COCCOc1cc([N+](=O)[O-])ccc1N1CCN(C)CC1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.51
LMNA P02545 4/20 0.51
MAPT P10636 1/20 0.51
MAPK1 P28482 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
KDM4E B2RXH2 1/20 0.51
WDR5 P61964 6/20 0.49
GAA P10253 2/20 0.49
KMT2A Q03164 2/20 0.49
POLB P06746 1/20 0.49
HTT P42858 2/20 0.48
SIRT6 Q8N6T7 1/20 0.48
MEN1 O00255 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10127604 0.89 ALDH1A1 (0.45) ALDH1A1LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL30736225 0.89 ALDH1A1 (0.52) ALDH1A1LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL21808580 0.89 ALDH1A1 (0.52) ALDH1A1LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL16501054 0.89 LMNA (0.51) ALDH1A1LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL12525222 0.87 KMT2A (0.54) ALDH1A1LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL29556577 0.84 ALDH1A1 (0.64) ALDH1A1LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL2062270 0.84 ALDH1A1 (0.64) ALDH1A1LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL30879319 0.84 CYP19A1 (0.54) ALDH1A1LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL2910168 0.83 HTT (0.47) ALDH1A1LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL30879346 0.83 CYP19A1 (0.45) ALDH1A1LMNAMAPTMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010496-B1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2010-08-25 EP disclosed
CN-101466682-A 4-anilinoquinolina-3-carboxamidas como inhibidores de la quinasa CSF-1R ASTRAZENECA AB (SE) 2009-06-24 CN disclosed
US-20090054411-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054411-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS CSF1R, CSF3R, FLT3 ALDH1A1 1650/4885LMNA 3715/4885MAPT 3289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.